CMO Indicia Production, specialising in the formulation and production of sterile liquid media (involving aseptic filling and the manufacture of ready-to-use microbiological media), has announced that Amundi Private Equity Funds (Amundi PEF) has acquired a stake in its capital. This minority interest is expected to support Indicia Production in its external growth, in order to increase its production capabilities.
Over the last seven years, Indicia Production has doubled its revenue and increased its staff from 30 to 45. The funds raised with Amundi PEF will help to support its expansion, including two acquisitions in France within an 18-month timescale, providing the group with additional production capabilities.
Indicia Production’s business activity is based on three product families:
- Ready-to-use microbiology culture environments for a client base, comprising distributors and industry providers of control tests for the pharmaceutical, food processing and cosmetics industries
- Sterile products and reagents for the pharmaceutical and cosmetics industries
- Medical devices
“Amundi PEF’s investment in Indicia Production is a major milestone in the history of our company, reflecting our ambition to drive Indicia Production forward through both organic growth and acquisitions,” said Stéphane Legastelois, chairman of Indicia Group. “Over the course of the next 18 months, we plan to acquire two companies; this will help us to significantly expand our production capabilities.”
“We are delighted to have invested in Indicia, a high value-added niche pharmaceutical manufacturer,” said Vinarom Vilaihongs, partner at Amundi PEF. “We are excited by the prospect of supporting Stéphane Legastelois in his policy of external growth.”
